Johns Hopkins Bloomberg School of Public Health: Diarrhea trials

The registry lists 12 Diarrhea studies with Johns Hopkins Bloomberg School of Public Health as lead sponsor. 2 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 3Phase 3 2Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Impact of Shigellosis and Recommended Treatment in ChildrenRecruitingNCT07433426Phase 2
• Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)RecruitingNCT06003816Not applicable
• Efficacy of Rifaximin in Preventing CampylobacteriosisCompletedNCT02280044Phase 2/3Results posted
• Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical OutcomesCompletedNCT00470158Phase 4Results posted
• Cholera-Hospital-Based-Intervention-for-7-daysCompletedNCT04008134Not applicable
• Low-dose Challenge Model With Enterotoxigenic E ColiCompletedNCT00844493Phase 1
• Dose-Finding Study of CS19 Expressing ETEC Challenge StrainsCompletedNCT00564863Phase 1
• Dose-Finding Study of WS6788A and LSN03-016011/A Enterotoxigenic E. Coli ETEC Challenge Strains That Express CS17CompletedNCT00564577Phase 1
• Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbDCompletedNCT00524004Phase 2
• Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/ICompletedNCT00435526Phase 1
• Efficacy of Bifidus DR10 and Oligo Saccharides / Micronutrient Fortification of MilkCompletedNCT00255385Phase 3
• Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge StrainsCompletedNCT00198796Phase 1